Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives
Pharmaceutics · 28.02.2026 · 18 (3) · 307
DOI: 10.3390/pharmaceutics18030307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.02.2026. Verfasst von Jonnathan Grossolli-Galvez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Inmunología, Departamento de Biología, Centro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Ch…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research and Development Agency of Chile, National Agency for Research and Development, National Doctoral Scholarship ANID.
Abstract (Originalsprache)
Lactococcus lactis, a safe food-grade lactic acid bacterium, has attracted increasing attention as a live biotherapeutic platform for mucosal vaccine development. Its genetic simplicity, absence of endotoxins, and availability of well-characterized inducible systems have enabled controlled expression and delivery of heterologous antigens and therapeutic molecules. This review highlights recent advances in the use of genetically modified L. lactis for mucosal immunization, focusing on expression technologies, routes of administration, and immune mechanisms relevant to protection or tolerance. Preclinical studies demonstrate its capacity to induce both mucosal and systemic immune responses against diverse pathogens, underscoring its potential as a safe and versatile vaccine chassis. Remaining challenges include regulatory harmonization, biosafety concerns, and the need for standardized manufacturing and evaluation frameworks. Together, these developments position L. lactis as a promising candidate for next-generation mucosal vaccines and live biotherapeutic products.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorio de Inmunología, Departamento de Biología, Centro de Biotecnología Acuícola, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago 91700022, Chile.
- Translational Immunology Laboratory, Department of Biological Sciences, Faculty of Life Sciences, Universidad Andres Bello, Santiago 8370146, Chile.
- Center for Research on Pandemic Resilience, Faculty of Life Sciences and Institute of Public Health, Universidad Andres Bello, Santiago 8370146, Chile.
- School of Veterinary Medicine, Faculty of Medicine and Health Sciences, Universidad Mayor, Santiago 8580745, Chile.
- Center for Biomedicine, Universidad Mayor, Santiago 8580745, Chile.
ORCID-Profile: Jonnathan Grossolli-Galvez, Mónica Imarai, Jorge A Soto, Abel E Vasquez
Förderung
- National Research and Development Agency of Chile
- National Agency for Research and Development
- National Doctoral Scholarship ANID
Zitieren
APA
Grossolli-Galvez, J., Imarai, M., Soto, J. A., & Vasquez, A. E. (2026). Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives. Pharmaceutics, 18(3), 307. https://doi.org/10.3390/pharmaceutics18030307
Vancouver
Grossolli-Galvez J, Imarai M, Soto JA, Vasquez AE. Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives. Pharmaceutics. 2026;18(3):307. doi:10.3390/pharmaceutics18030307
BibTeX
@article{GrossolliGalvez2026,
author = {Grossolli-Galvez, Jonnathan and Imarai, Mónica and Soto, Jorge A and Vasquez, Abel E},
title = {Lactococcus lactis as a New Strategy for Oral Vaccination: Current Insights and Future Perspectives},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {3},
pages = {307},
doi = {10.3390/pharmaceutics18030307}
}
EUVIMED